DUBLIN--(BUSINESS WIRE)-- Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the first patient has been enrolled in a Phase 3 clinical trial in Japan evaluating TEPEZZA for the treatment of ...
-- Teprotumumab is marketed under the brand name TEPEZZA® in the United States-- The primary efficacy endpoint is proptosis response rate at Week 24, measured by the percentage of participants with at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback